简介：由《中国血液净化》杂志社主办的“慢性肾脏病一体化治疗研讨班”[项目编号：2017-03-05-013（国）]将于2017年12月1日至3日在河南省新乡市长垣县举办。流行病学调查显示,我国慢性肾脏病患病率高达10.8%。慢性肾脏病不断进展,部分患者终致尿毒症,或在进入尿毒症前发生心脑血管事件甚至死亡,严重危害人类健康。对于慢性肾脏病患者,其治疗目的是要治疗可治的原发病、延缓肾病进展、预防心脑血管事件、纠正慢性肾脏病并发症;

简介：为了从源头上治理食品造假，保证上市食品的安全，国家已对部分日用食品实行了市场准入制度，消费者在选购这些食品时一定要认清QS标志。同时还要对食品生产许可证编号有所了解，以辨别其是否为正规企业生产的产品。

简介：

简介：摘要目的评价C-反应蛋白与白细胞检测在感染性疾病中的鉴别诊断作用。方法研究对象取2014年10月～2015年10月本院感染性疾病患儿53例，设为实验组；取同期本院非感染性疾病患儿53例，设为对照组。检测两组C-反应蛋白与白细胞，组间比较。结果组间比较，实验组阳性率高；实验组组内比较，细菌性肺炎阳性率高，诊断特异性为95.7%，敏感性为91.2%，有显著差异（P<0.05），具统计学意义。结论CRP及WBC检测在感染性疾病鉴别诊断作用较大，有极大诊断意义，需推广。

简介：【摘要】 目的 本文重点围绕健康体检人群1004例血脂异常的调查分析及护理干预进行深入研究。方法 从2020年8月20日起至2021年8月21日止，选取在我院接受体检的健康体检人群1004例血脂异常者为本次研究对象，并以年龄、性别区分后，对血脂异常者进行统计，分析血脂异常是否与年龄及性别有关，另外在研究期间将患者随机分成相同人数的两组，分在研究组的患者实施具有针对性的护理措施，分在参照组患者常规护理干预，对比两组护理效果。结果 不同年龄段人群血脂异常情况存在明显性差异，年龄超过60岁者相比于低于40岁者及40-60者血脂异常人数更多，数据差异较明显，具有统计学意义（P＜0.05）；从性别上看，血脂异常情况无明显差异性（P＞0.05）。两组护理前血脂异常人数相同，在护理后，研究组123例血脂异常者，构成比24.50%显低，参照组300例血脂异常者，构成比59.76%较高，两组差异明显（P＜0.05）。

简介：摘要病案编号是病案的识别标志，病案编号管理在病案管理工作中属于基础性工作，又占有非常重要的地位，病案编号是查找病人资料的唯一途径，加强病案编号管理可使病案管理工作更有序地进行，使病案资料能够更充分、高效地被利用。本文从病案编号的方法、号码的分派（包括号码分派主要方式、号码分派控制）、病案连锁方面进行介绍，以期为病案管理工作提供参考。

简介：AbstractBackground:Innovative coronavirus disease 2019 (COVID-19) vaccines, with elevated global manufacturing capacity, enhanced safety and efficacy, simplified dosing regimens, and distribution that is less cold chain-dependent, are still global imperatives for tackling the ongoing pandemic. A previous phase I trial indicated that the recombinant COVID-19 vaccine (V-01), which contains a fusion protein (IFN-PADRE-RBD-Fc dimer) as its antigen, is safe and well tolerated, capable of inducing rapid and robust immune responses, and warranted further testing in additional clinical trials. Herein, we aimed to assess the immunogenicity and safety of V-01, providing rationales of appropriate dose regimen for further efficacy study.Methods:A randomized, double-blind, placebo-controlled phase II clinical trial was initiated at the Gaozhou Municipal Centre for Disease Control and Prevention (Guangdong, China) in March 2021. Both younger (n = 440; 18-59 years of age) and older (n = 440; ≥60 years of age) adult participants in this trial were sequentially recruited into two distinct groups: two-dose regimen group in which participants were randomized either to follow a 10 or 25 μg of V-01 or placebo given intramuscularly 21 days apart (allocation ratio, 3:3:1, n = 120, 120, 40 for each regimen, respectively), or one-dose regimen groups in which participants were randomized either to receive a single injection of 50 μg of V-01 or placebo (allocation ratio, 3:1, n = 120, 40, respectively). The primary immunogenicity endpoints were the geometric mean titers of neutralizing antibodies against live severe acute respiratory syndrome coronavirus 2, and specific binding antibodies to the receptor binding domain (RBD). The primary safety endpoint evaluation was the frequencies and percentages of overall adverse events (AEs) within 30 days after full immunization.Results:V-01 provoked substantial immune responses in the two-dose group, achieving encouragingly high titers of neutralizing antibody and anti-RBD immunoglobulin, which peaked at day 35 (161.9 [95% confidence interval [CI]: 133.3-196.7] and 149.3 [95% CI: 123.9-179.9] in 10 and 25 μg V-01 group of younger adults, respectively; 111.6 [95%CI: 89.6-139.1] and 111.1 [95%CI: 89.2-138.4] in 10 and 25 μg V-01 group of older adults, respectively), and remained high at day 49 after a day-21 second dose; these levels significantly exceed those in convalescent serum from symptomatic COVID-19 patients (53.6, 95%CI: 31.3-91.7). Our preliminary data show that V-01 is safe and well tolerated, with reactogenicity predominantly being absent or mild in severity and only one vaccine-related grade 3 or worse AE being observed within 30 days. The older adult participants demonstrated a more favorable safety profile compared with those in the younger adult group: with AEs percentages of 19.2%, 25.8%, 17.5% in older adults vs. 34.2%, 23.3%, 26.7% in younger adults at the 10, 25 μg V-01 two-dose group, and 50 μg V-01 one-dose group, respectively.Conclusions:The vaccine candidate V-01 appears to be safe and immunogenic. The preliminary findings support the advancement of the two-dose, 10 μg V-01 regimen to a phase III trial for a large-scale population-based evaluation of safety and efficacy.Trial Registration:http://www.chictr.org.cn/index.aspx (No. ChiCTR2100045107, http://www.chictr.org.cn/showproj.aspx? proj=124702).

简介：摘要实验中经常需要对大鼠进行标记，1-9号的标记相对简单，单一染料即可。但在大鼠样本量较大的情况下，通常用两种不同颜色的染料对大鼠进行标记。本文中使用苦味酸溶液对样本量100内的大鼠进行标记，简单方便、辨识快捷，是一种经济有效的标记方法。

简介：题名应以简明、确切的词语反映文章中最重要的特定内容,要符合编制题录、索引和检索的有关原则,并有助于选定主题词。中文题名一般不宜超过20个字,必要时可加副题名。英文题名应与中文题名含义一致。题名应避免使用非公知公用的缩写词、字符、代号,尽量不出现数学公式和化学式。

简介：▲题名应以简明、确切的词语反映文章中最重要的特定内容，要符合编制题录、索引和检索的有关原则，并有助于选定主题词。▲中文题名一般不宜超过20个字，必要时可加副题名。

简介：▲题名应以简明、确切的词语反映文章中最重要的特定内容,要符合编制题录、索引和检索的有关原则,并有助于选定主题词。▲中文题名一般不宜超过20个字,必要时可加副题名。▲英文题名应与中文题名含义一致。▲题名应避免使用非公知公用的缩写词、字符、代号,尽量不出现数学公式和化学式。

简介：【摘要】目的：探究分析带状疱疹后遗神经痛（Postherpetic neuralgia，PHN）病人接受中药联合揿针治疗所产生的作用。方法：选用2022年4月至2023年4月间我院的124例PHN病人，随机将其均分成2组，观察组和对照组各62例。对照组按西中药进行治疗，观察组病人采用中药联合揿针加用揿针进行医治。对两组病人的总有效率、不良反应发生率和生活质量评分进行对比分析。结果：干预后观察组的治疗有效率以及生活质量优于观察组（P<0.05）；观察组的不良事件发生率比对照组少（P<0.05)；干预后，观察组的VAS疼痛评分低于对照组（P<0.05）。结论：中药联合揿针治疗PHN具有显著的临床疗效，可有效提升治疗效果、改善疼痛症状，减少不良反应，为该病的治疗提供一种安全有效的方法。

简介：AbstractObjective:To study the epidemiology of leprosy in China in 2019 and give suggestions to improve future leprosy control activities.Methods:We collected leprosy data from the Leprosy Management Information System in China, which includes data from 31 Chinese provinces, autonomous regions, and municipalities, except for Hong Kong, Macao, and Taiwan. We then performed a descriptive analysis of these data.Results:A total of 464 new leprosy cases were reported nationwide in 2019, with a case detection rate of 0.033/100,000. The proportions of children younger than 15 years, multibacillary cases, and cases with World Health Organization grade 2 disability were 1.3%, 90.3%, and 21.6%, respectively. A total of 2,219 leprosy cases were registered in China by the end of 2019, giving a prevalence rate of 0.158/100,000. Fifty-six counties had a prevalence rate of more than 1/100,000, and most of them were located in Southwest China. There were 31 reported relapse cases.Conclusion:The prevalence of leprosy has improved continuously throughout China, but the southwest region is still an area of concern.

简介：各位编委、各位审稿专家、各位读者:您好!律回春晖渐,万象始更新。在2019年新春到来之际,《中国骨质疏松杂志》向各位编委、各位审稿专家、各位读者致以诚挚的问候!

简介：《炎黄世界》编辑部同志们；你们好!读责刊今年第二期发表的《我们的“文化”怎么啦!》一文，感觉是一篇脍炙人口、文道俱佳的评论文章。本人十分赞同作者的观点，也非常赞赏作品的文采。资中筠老师不仅积极主张国人要重视学好母语中文，而且身体力行，认真实践，令人敬佩。

简介：无

简介：摘要目的探讨新增病区物品管理的有效方法。方法新增病区采用标识编号管理，实施物品定置。结果物品规范放置，减轻新进科室所有人员环境陌生感，改善了病区的环境、提高了医护人员的工作效率、降低了护理差错发生率、增加了医患双方的满意度。结论对新增病区物品实施标识编号管理，是一种科学、系统、有效的方法。

简介：无

简介：1题目1．1用最简洁、最恰当的词语构成的逻辑组合反映论文的特定内容。

简介：